Relationship between Ribosomal Protein S6-pS240 Expression and other Prognostic Factors in Non-Special Type Invasive Breast Cancer

Çuperjani, Frederik; Gashi, Lumturije; Kurshumliu, Fisnik; Dreshaj, Shemsedin; Selimi, Fitim

doi:10.1159/000491427

Cited by 7 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there was no significant difference in relapse-free survival (RFS) between cancer patients with high p-RPS6 levels and those with low p-RPS6 levels. In addition, high-level expression of p-RPS6 (S240) correlated with high Ki67 expression and short overall survival (OS) of breast cancer patients [ 450 ].…”

Section: Rps6 In Cancermentioning

confidence: 99%

Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

You

Park

et al. 2021

IJMS

View full text Add to dashboard Cite

Ribosomal protein S6 (RPS6) is a component of the 40S small ribosomal subunit and participates in the control of mRNA translation. Additionally, phospho (p)-RPS6 has been recognized as a surrogate marker for the activated PI3K/AKT/mTORC1 pathway, which occurs in many cancer types. However, downstream mechanisms regulated by RPS6 or p-RPS remains elusive, and the therapeutic implication of RPS6 is underappreciated despite an approximately half a century history of research on this protein. In addition, substantial evidence from RPS6 knockdown experiments suggests the potential role of RPS6 in maintaining cancer cell proliferation. This motivates us to investigate the current knowledge of RPS6 functions in cancer. In this review article, we reviewed the current information about the transcriptional regulation, upstream regulators, and extra-ribosomal roles of RPS6, with a focus on its involvement in cancer. We also discussed the therapeutic potential of RPS6 in cancer.

show abstract

Section: Rps6 In Cancermentioning

confidence: 99%

Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

You

Park

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Overexpression of pS6 ribosomal protein has also been reported to be related to worse overall, shorter metastatic-free and disease-free survival in lung, ovarian and breast cancer as well as in renal cell carcinomas [23][24][25][26] .…”

Section: Discussionmentioning

confidence: 99%

Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

Rüschoff

Felley‐Bosco²,

Weynand³

et al. 2022

Modern Pathology

View full text Add to dashboard Cite

Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Although histology and pathologic stage are important prognostic factors, better prognostic biomarkers are needed. The ribosomal protein S6 is a downstream target of the phosphatidylinositol 3-kinase (PI3K) pathway involved in protein synthesis and cell proliferation. In previous studies, low phosphorylated S6 (pS6) immunoreactivity was significantly correlated with longer progression-free survival (PFS) and overall survival (OS) in PM patients. We aimed to correlate pS6 expression to clinical data in a large multi-centre PM cohort as part of the European Thoracic Oncology Platform (ETOP) Mesoscape project. Tissue Micro Arrays (TMAs) of PM were constructed and expression of pS6 was evaluated by a semi-quantitatively aggregate H-score. Expression results were correlated to patient characteristics as well as OS/PFS. pS6 IHC results of 364 patients from 9 centres, diagnosed between 1999 and 2017 were available. The primary histology of included tumours was epithelioid (70.3%), followed by biphasic (24.2%) and sarcomatoid (5.5%). TMAs included both treatment-naïve and tumour tissue taken after induction chemotherapy. High pS6 expression (181 patients with H-score>1.41) was significantly associated with less complete resection. In the overall cohort, OS/PFS were not significantly different between pS6-low and pS6-high patients. In a subgroup analysis non-epithelioid (biphasic and sarcomatoid) patients with high pS6 expression showed a significantly shorter OS (p < 0.001, 10.7 versus 16.9 months) and PFS (p < 0.001, 6.2 versus 10.8 months). In subgroup analysis, in non-epithelioid PM patients high pS6 expression was associated with significantly shorter OS and PFS. These exploratory findings suggest a clinically relevant PI3K pathway activation in non-epithelioid PM which might lay the foundation for future targeted treatment strategies.

show abstract

“…Four hundred and three documents were reviewed in full text to assess eligibility. Finally, 65 documents were included in the evidence synthesis [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 ...…”

Section: Resultsmentioning

confidence: 99%

“…The surgical treatments for breast cancer have changed dramatically, from radical mastectomy to breast-conserving surgery [ 83 ]. About one-third of women with breast cancer in Kosovo still have a mastectomy [ 73 ]. Additionally, in the case of cervical cancer treatment, there are issues with the quality of the services, the coordination of care, and the establishment of a definitive diagnosis and treatment [ 48 ].…”

Section: Resultsmentioning

confidence: 99%

Management of Non-Communicable Diseases in Kosovo: A Scoping Review

Hoxha

Apuk

Kryeziu

et al. 2023

IJERPH

View full text Add to dashboard Cite

Background—Non-communicable diseases (NCDs) affect a growing share of the population in Kosovo. The country faces challenges with NCDs management, specifically detecting, screening, and treating people with NCDs. Objective—To assess the management of NCDs, including the inputs that influence the provision of NCDs and outcomes of NCD management. Eligibility criteria—Studies had to report NCD management in Kosovo. Sources of evidence—We systematically searched Google Scholar, PubMed, Scopus, and Web of Science. Charting methods—The data were charted by two researchers. In addition, we extracted data on general study details and design and information on the management and outcomes of NCDs in Kosovo. Synthesis of results—For the mix of studies that were included in the review, thematic narrative synthesis was used. We developed a conceptual framework based on health production core components to analyze the data. Results—Kosovo’s health care system is available to provide basic care for patients with NCDs. However, there are serious limitations in the availability of key inputs providing care, i.e., funding, medicines, supplies, and medical staff. Additionally, in terms of the management of NCDs, there are areas for improvement, such as limited application of clinical pathways and guidelines and issues with referrals of patients among levels and sectors of care. Finally, it is worth noting that there is overall limited information on NCD management and outcomes. Conclusions—Kosovo provides only basic services and treatment of NCDs. The data reporting the existing situation on NCD management are limited. The inputs from this review are helpful for existing policy efforts by the government aimed to enhance NCD care in Kosovo. Funding—This study was funded by World Bank Grant. WeBa NCD Trust Fund (P170638).

show abstract

Relationship between Ribosomal Protein S6-pS240 Expression and other Prognostic Factors in Non-Special Type Invasive Breast Cancer

Cited by 7 publications

References 29 publications

Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

Management of Non-Communicable Diseases in Kosovo: A Scoping Review

Contact Info

Product

Resources

About